At the 2023 Grand Challenges Annual Meeting, Bill Gates, announced new investments to advance access to mRNA research and vaccine manufacturing technology that will support low- and middle-income countries.

Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin®.

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

SPARTA technology to accelerate the development, manufacture and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs.

Thermo Fisher Scientific TSX and TDE Series ultra-low freezers are tested according to ISO 14644-14 and designated ISO Class 5.5; operational; 0.1 μm, 0.2 μm, 0.3 μm, 0.5 μm, 1.0 μm, contributing to the safe and effective development of therapies.

Under the new agreement, Integrated DNA Technologies (IDT) will sell Aldevron cGMP-manufactured CRISPR nucleases to enable customers to rapidly transition from discovery to clinic.

Form Bio, announced capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates.